Novavax (NVAX) Stock: Buy, Sell, or Hold?
NVAX - Novavax Inc
$10.60
-0.21 (-1.94%)
▼
5d:
+0.0%
30d:
+4.74%
90d:
+8.83%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When NVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NVAX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NVAX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NVAX is currently trading at $10.60, which is considered extended relative to its 30-day fair value range of $9.36 to $10.59. From a valuation perspective, the stock is trading at a discount (Forward PE: -47.3) compared to its historical average (35.1). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, NVAX is in a uptrend. Immediate support is located at $9.76, while resistance sits at $11.11.
Market Sentiment: NVAX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.00 (+32.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NVAX is in a uptrend. Immediate support is located at $9.76, while resistance sits at $11.11.
Market Sentiment: NVAX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.00 (+32.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.36 -
$10.59
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
Protect Your Profits
Holding NVAX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.1% below Wall St target ($14.00)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.36 -
$10.59
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.76
Resistance Level
$11.11
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-47.26
Wall Street Target
$14.00
(+32.1%)
Revenue Growth (YoY)
-76.3%
Earnings Growth (YoY)
-38.1%
Profit Margin
-59.9%
PE vs Historical
-47.3 vs 35.1
CHEAP
Share & Embed Analysis
Last updated: October 02, 2026 5:44 AM ET
Data refreshes hourly during market hours. Next update: 6:44 AM
Data refreshes hourly during market hours. Next update: 6:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 63 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 60 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 68 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 48 HOLD |
Advanced NVAX Option Strategies
Professional options setups generated by AI based on today's NVAX price and gamma walls.
